Validating national registry data for randomized trials: comparison of registry-derived cardiovascular events with and without adjudication in the BETAMI-DANBLOCK trial
- 4 April 2026
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (6) , 903-911
Abstract
Aims: Registry-based randomized clinical trials are increasingly applied in clinical research, providing advantages in feasibility and data capture. However, registry-based data may introduce bias through misclassification or missing information. Methods and results: In the BETAMI-DANBLOCK trial, 5574 patients with myocardial infarction (MI) and no heart failure were randomized to beta-blocker or no beta-blocker therapy. The primary endpoint events (all-cause mortality, MI, ischemic stroke, heart failure, unplanned coronary revascularization, and malignant ventricular arrhythmias) were identified from the Danish/Norwegian national patient registries, self-reported questionnaires, and medical records. All registry-identified events, except all-cause mortality, underwent blinded adjudication. We compared non-adjudicated and adjudicated events by calculating incidence rates and hazard ratios (HRs) for beta-blocker therapy vs. controls. National registries captured 99.7% of primary endpoint events registered by self-report and medical records. Of the primary endpoint events identified through the registries, 75% were confirmed by adjudication (incidence rate 6.23 vs. 4.43/100 person-years). The confirmation rate was lower during the first 6 months and varied by event type (from 92% for ischaemic stroke to 45% for unplanned coronary revascularizations and heart failure). Estimated treatment effects were consistent for the primary endpoint with non-adjudicated and adjudicated events (HR 0.88, 95% confidence interval (CI): 0.78–0.98 and HR 0.85, 95% CI: 0.75–0.98, respectively), with no apparent differences across event types except for heart failure and revascularization. Conclusion: Registry data provided effect estimates of beta-blockers comparable to adjudicated data. However, adjudication substantially reduced the number of cardiovascular endpoint events and event-specific misclassification appeared, particularly during the first months after the index event. Trial registration number: BETAMI-DANBLOCK ClinicalTrials.gov numbers, NCT03646357 and NCT03778554Keywords
Funding Information
- Health South-East research programme in Norway (2017205)
- Norges Forskningsråd (302454)
- Hjerteforeningen (18-R124-A8323-22091)
- Novo Nordisk Fonden (NNF18OC0034582)
This publication has 26 references indexed in Scilit:
- Data quality assessment in the SWEDEHEART registry: Insights from serial audits on completeness and accuracyAmerican Heart Journal, 2025
- Independence of clinical events committees: A consensus statement from clinical research organizationsAmerican Heart Journal, 2022
- Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial InfarctionNew England Journal of Medicine, 2021
- In-Hospital Cardiac ArrestJAMA, 2019
- International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and designAmerican Heart Journal, 2018
- Oxygen Therapy in Suspected Acute Myocardial InfarctionNew England Journal of Medicine, 2017
- Bivalirudin versus Heparin Monotherapy in Myocardial InfarctionNew England Journal of Medicine, 2017
- Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research?Journal of Clinical Epidemiology, 2016
- Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trialAmerican Heart Journal, 2014
- Validity of coronary heart diseases and heart failure based on hospital discharge and mortality data in the Netherlands using the cardiovascular registry Maastricht cohort studyEuropean Journal of Epidemiology, 2009